What question did this study set out to answer?

This research investigates how inhibitors of mitotic kinases induce a senescence state that enhances anti-tumor immunity.

Abstract LB150: Senescence as an immune tolerance breaker: Inhibitors of mitotic kinases TTK (Mps1) and AURKA induce pro-immunogenic senescence that primes the tumor microenvironment for immunotherapy via cGAS-STING signaling

View Full Paper

Ask AI

Bookmark

Authors

Findings reveal that mitotic kinase inhibition enhances immune responses in tumors, suggesting new immunotherapy strategies.

This research investigates how inhibitors of mitotic kinases induce a senescence state that enhances anti-tumor immunity.
Examined therapy-induced senescence (TIS) using mitotic kinase inhibitors in various tumor models in vitro and in vivo.
Conducted transcriptional and secretome profiling to assess immune-related changes in senescent cells.
Evaluated the impact of a senolytic agent on the senescence-associated secretory phenotype (SASP).
Mitotic kinase inhibitors increased inflammation and immune gene expression in senescent cells.
Senolytic treatment altered SASP to promote pro-immunogenic characteristics, activating cytotoxic T cells.
In vivo studies showed enriched tumor microenvironments with activated CD8+ T and NK cells after treatment, demonstrating enhanced anti-tumor effects.

Capece et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Findings reveal that mitotic kinase inhibition enhances immune responses in tumors, suggesting new immunotherapy strategies.

This research investigates how inhibitors of mitotic kinases induce a senescence state that enhances anti-tumor immunity.
Examined therapy-induced senescence (TIS) using mitotic kinase inhibitors in various tumor models in vitro and in vivo.
Conducted transcriptional and secretome profiling to assess immune-related changes in senescent cells.
Evaluated the impact of a senolytic agent on the senescence-associated secretory phenotype (SASP).
Mitotic kinase inhibitors increased inflammation and immune gene expression in senescent cells.
Senolytic treatment altered SASP to promote pro-immunogenic characteristics, activating cytotoxic T cells.
In vivo studies showed enriched tumor microenvironments with activated CD8+ T and NK cells after treatment, demonstrating enhanced anti-tumor effects.

Capece et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark